Humira tops list of drugs with unwarranted US price hikesAbbVie’s Humira heads a list of seven medicines that collectively contributed to a $5.1 billion increase in US Share XHumira tops list of drugs with unwarranted US price hikeshttps://pharmaphorum.com/news/humira-tops-list-of-drugs-with-unwarranted-us-price-hikes/
Cancer update buoys Amgen despite Q2 sales fallAmgen’s second quarter revenues were down 3% as competition pegged back its off-patent drugs Sensipar and Neulasta, but Share XCancer update buoys Amgen despite Q2 sales fallhttps://pharmaphorum.com/news/cancer-update-buoys-amgen-despite-q2-sales-fall/
Napp launches Neulasta biosimilar in UKNapp’s Pelmeg, a biosimilar of Amgen’s cancer drug Neulasta (pegfilgrastim), has been launched in the UK following approval Share XNapp launches Neulasta biosimilar in UKhttps://pharmaphorum.com/news/napp-launches-neulasta-biosimilar-in-uk/
Amgen faces first Neulasta biosimilar rival as FDA approves Mylan drugAmgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar Share XAmgen faces first Neulasta biosimilar rival as FDA approves Mylan drughttps://pharmaphorum.com/news/amgen-neulasta-biosimilar-fda-mylan-fulphila/
